AccuMetab™ Human CYP3A5 Enzyme, Catalytically Active with Cytochrome b5
CAT#: ITS-0426-YL67
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP3A5 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
By incorporating Cytochrome b5, the Phase I metabolic turnover of CYP3A5 is elevated to match true physiological conditions. This enhancement is vital for highly sensitive pharmacogenetic ADME assays requiring precise quantification of drug metabolite formation rates.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Essential for precise pharmacogenetic quantification; Matches true in vivo rapid-turnover conditions; Available in multiple reductase ratios
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.